{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:47:47Z","timestamp":1790801267671,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Cognitive impairments following post-stroke significantly hinder neurological recovery and exacerbate patient morbidity, underscoring urgent need for effective therapeutic strategies. Vortioxetine (VTX), a prominent Selective Serotonin Reuptake Inhibitor (SSRI), boasts notable antidepressant, cognition-enhancing, and anti-inflammatory properties. This investigation delves into VTX\u2019s influence on motor skills, spatial learning-memory capabilities, and depressive behaviors in Middle Cerebral Artery Occlusion (MCAO) rats, alongside its underlying mechanisms. Our findings reveal that while VTX fails to entirely reverse ischemic-reperfusion damage, it substantially ameliorates spontaneous locomotor functions, augments post-stroke learning-memory capacities, and exhibits potent antidepressant and anxiety-like efficacy. Preliminary data propose that these beneficial effects may stem from inflammation modulation via the Toll-Like Receptor 2 (TLR-2)\/Nuclear Factor-Kappa B (NF-<jats:italic>\u03ba<\/jats:italic>B) signaling pathway. Collectively, our work underscores VTX\u2019s promising role in enhancing motor, cognitive functions, and mitigating depressive symptoms following cerebrovascular accidents, potentially through inflammation regulation. These insights pave the way for novel interventions addressing post-stroke complications, warranting further exploration.<\/jats:p>","DOI":"10.3389\/fphar.2025.1555079","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:57:12Z","timestamp":1741766232000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Vortioxetine alleviates motor, cognitive and emotional disorders in post-stroke rats by regulating the TLR-2\/NF-\u03baB pathway"],"prefix":"10.3389","volume":"16","author":[{"given":"Ziqiang","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqiang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jad.2023.01.074","article-title":"Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: an updated analysis of efficacy and tolerability","volume":"328","author":"Adair","year":"2023","journal-title":"J. Affect. Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"603979","DOI":"10.3389\/fphar.2020.603979","article-title":"Vortioxetine prevents lipopolysaccharide-induced memory impairment without inhibiting the initial inflammatory cascade","volume":"11","author":"Alboni","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s13311-016-0483-x","article-title":"Inflammation and stroke: an overview","volume":"13","author":"Anrather","year":"2016","journal-title":"Neurotherapeutics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/01.wnl.0000266625.31615.f6","article-title":"Galantamine treatment of vascular dementia: a randomized trial","volume":"69","author":"Auchus","year":"2007","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics-2017 update: a report from the American heart association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jad.2023.06.024","article-title":"Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: the MEMORY study","volume":"338","author":"Christensen","year":"2023","journal-title":"J. Affect. Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: when the immune system subjugates the brain","volume":"9","author":"Dantzer","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"119865","DOI":"10.1016\/j.lfs.2021.119865","article-title":"Vortioxetine mitigates neuronal damage by restricting PERK\/eIF2\u03b1\/ATF4\/CHOP signaling pathway in rats subjected to focal cerebral ischemia-reperfusion","volume":"283","author":"Emam","year":"2021","journal-title":"Life Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jad.2020.11.106","article-title":"Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI\/SNRI treatment","volume":"283","author":"Fagiolini","year":"2021","journal-title":"J. Affect. Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"15114","DOI":"10.3390\/ijms232315114","article-title":"Pathophysiology and current drug treatments for post-stroke depression: a review","volume":"23","author":"Frank","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1177\/1359105315587140","article-title":"Clarifying the associations between anxiety, depression and fatigue following stroke","volume":"21","author":"Galligan","year":"2016","journal-title":"J. Health Psychol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jad.2021.02.075","article-title":"Safety and efficacy of vortioxetine on depressive symptoms and cognition in post-stroke patients: a pilot study","volume":"286","author":"Gamberini","year":"2021","journal-title":"J. Affect. Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/npp.2014.222","article-title":"Effects of inflammation on hippocampus and substantia nigra responses to novelty in healthy human participants","volume":"40","author":"Harrison","year":"2015","journal-title":"Neuropsychopharmacol. (New York, N.Y.)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00213-020-05452-9","article-title":"Vortioxetine administration attenuates cognitive and synaptic deficits in 5\u00d7FAD mice","volume":"237","author":"Jiang","year":"2020","journal-title":"Psychopharmacologia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2409345121","DOI":"10.1073\/pnas.2409345121","article-title":"Secondary thalamic dysfunction underlies abnormal large-scale neural dynamics in chronic stroke","volume":"121","author":"Johnston","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.brainres.2005.02.038","article-title":"Interaction between neuropeptide Y and alpha-melanocyte stimulating hormone in amygdala regulates anxiety in rats","volume":"1043","author":"Kokare","year":"2005","journal-title":"Brain Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.12740\/PP\/OnlineFirst\/151570","article-title":"Vortioxetine - pharmacological properties and use in mood disorders. The current state of knowledge","volume":"57","author":"Krupa","year":"2023","journal-title":"Psychiatr. Pol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1161\/01.str.20.1.84","article-title":"Reversible middle cerebral artery occlusion without craniectomy in rats","volume":"20","author":"Longa","year":"1989","journal-title":"Stroke"},{"key":"B19","doi-asserted-by":"publisher","first-page":"9113","DOI":"10.1038\/s41598-021-88462-7","article-title":"Vortioxetine ameliorates anhedonic-like behaviour and promotes strategic cognitive performance in a rodent touchscreen task","volume":"11","author":"Martis","year":"2021","journal-title":"Sci. Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.genhosppsych.2020.06.011","article-title":"Post-stroke depression: a 2020 updated review","volume":"66","author":"Medeiros","year":"2020","journal-title":"Gen. Hosp. Psychiatry."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1161\/CIRCULATIONAHA.109.851881","article-title":"Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis","volume":"120","author":"Monaco","year":"2009","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"108977","DOI":"10.1016\/j.neuropharm.2022.108977","article-title":"Vortioxetine ameliorates motor and cognitive impairments in the rotenone-induced Parkinson's disease via targeting TLR-2 mediated neuroinflammation","volume":"208","author":"Nemutlu","year":"2022","journal-title":"Neuropharmacology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jocn.2005.07.005","article-title":"Inflammation following stroke","volume":"13","author":"Nilupul","year":"2006","journal-title":"J. Clin. Neurosci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"114848","DOI":"10.1016\/j.celrep.2024.114848","article-title":"Post-stroke hippocampal neurogenesis is impaired by microvascular dysfunction and PI3K signaling in cerebral amyloid angiopathy","volume":"43","author":"Osborne","year":"2024","journal-title":"Cell Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S0140-6736(18)31269-8","article-title":"Prevention of stroke: a global perspective","volume":"392","author":"Pandian","year":"2018","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1080\/14656566.2017.1334765","article-title":"Advances in antidepressants for treating post-stroke depression","volume":"18","author":"Paolucci","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nri2015","article-title":"Systemic infections and inflammation affect chronic neurodegeneration","volume":"7","author":"Perry","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1176\/appi.ajp.2015.15030363","article-title":"Post-stroke depression: a review","volume":"173","author":"Robinson","year":"2016","journal-title":"Am. J. Psychiatry."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1161\/STROKEAHA.109.570077","article-title":"Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size","volume":"41","author":"Roman","year":"2010","journal-title":"Stroke"},{"key":"B30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/01.NURSE.0000422646.06254.1c","article-title":"Recognizing poststroke depression","volume":"42","author":"Schneider","year":"2012","journal-title":"Nursing"},{"key":"B32","doi-asserted-by":"publisher","first-page":"176929","DOI":"10.1016\/j.ejphar.2024.176929","article-title":"Vortioxetine ameliorates experimental autoimmune encephalomyelitis model of multiple sclerosis in mice via activation of PI3K\/Akt\/CREB\/BDNF cascade and modulation of serotonergic pathway signaling","volume":"982","author":"Shafiek","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"115128","DOI":"10.1016\/j.bbr.2024.115128","article-title":"Prenatal exposure to vortioxetine and vilazodone: impact on depressive- and anxiety-like behavioral manifestations in young rat offspring","volume":"471","author":"Singh","year":"2024","journal-title":"Behav. Brain Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1017\/S1092852915000358","article-title":"Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters","volume":"20","author":"Stahl","year":"2015","journal-title":"CNS Spectr."},{"key":"B35","doi-asserted-by":"publisher","first-page":"105676","DOI":"10.1016\/j.neuint.2024.105676","article-title":"Echinatin protects from ischemic brain injury by attenuating NLRP3-related neuroinflammation","volume":"175","author":"Sun","year":"2024","journal-title":"Neurochem. Int."},{"key":"B36","doi-asserted-by":"publisher","first-page":"106085","DOI":"10.1016\/j.intimp.2019.106085","article-title":"MPMBP down-regulates Toll-like receptor (TLR) 2 ligand-induced proinflammatory cytokine production by inhibiting NF-\u03baB but not AP-1 activation","volume":"79","author":"Tamai","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"272","DOI":"10.4103\/0028-3886.314574","article-title":"Post-stroke movement disorders: clinical spectrum, pathogenesis, and management","volume":"69","author":"Tater","year":"2021","journal-title":"Neurol. India"},{"key":"B38","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jad.2020.03.022","article-title":"Antidepressants of different classes cause distinct behavioral and brain pro- and anti-inflammatory changes in mice submitted to an inflammatory model of depression","volume":"268","author":"Tomaz","year":"2020","journal-title":"J. Affect. Disord."},{"key":"B39","doi-asserted-by":"publisher","first-page":"C135-C153","DOI":"10.1152\/ajpcell.00136.2018","article-title":"Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke","volume":"316","author":"Yang","year":"2019","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3390\/ijms19020513","article-title":"Inhibition of phosphodiesterase 4 by FCPR03 alleviates lipopolysaccharide-induced depressive-like behaviors in mice: involvement of p38 and JNK signaling pathways","volume":"19","author":"Yu","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"821270","DOI":"10.3389\/fphar.2022.821270","article-title":"Shugan jieyu capsule in post-stroke depression treatment: from molecules to systems","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3892\/ijmm.2021.5070","article-title":"Neuronal injuries in cerebral infarction and ischemic stroke: from mechanisms to treatment (Review)","volume":"49","author":"Zhao","year":"2022","journal-title":"Int. J. Mol. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"149307","DOI":"10.1016\/j.brainres.2024.149307","article-title":"Altered callosal morphology in post-stroke cognitive impairment","volume":"1847","author":"Zhou","year":"2024","journal-title":"Brain Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1021\/acschemneuro.8b00273","article-title":"Correction to discovery ofN -alkyl catecholamides as selective phosphodiesterase-4 inhibitors with anti-neuroinflammation potential exhibiting antidepressant-like effects at non-emetic doses","volume":"9","author":"Zhou","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1124\/jpet.116.239608","article-title":"Novel phosphodiesterase 4 inhibitor FCPR03 alleviates lipopolysaccharide-induced neuroinflammation by regulation of the cAMP\/PKA\/CREB signaling pathway and NF-\u03baB inhibition","volume":"362","author":"Zou","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1555079\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:57:15Z","timestamp":1741766235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1555079\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":45,"alternative-id":["10.3389\/fphar.2025.1555079"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1555079","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"article-number":"1555079"}}